Page 98 - 南京医科大学自然科学版第1期
P. 98

南京医科大学学报(自然科学版)                                  第41卷第1期
               · 92  ·                    Journal of Nanjing Medical University(Natural Sciences)   2021年1月


             ·临床研究·

              ⅠB~ⅡA1期宫颈癌术后合并中危因素患者化疗或放疗疗效及

              生活质量分析



              杨颖倩 ,周德兰 ,韩男男 ,李             甦 ,韩素萍    2*
                             2
                                     2
                     1
                                             3
               南京中医药大学附属医院妇科,江苏              南京   210029;南京医科大学第一附属医院妇产科,江苏                南京   210036;南京医科
              1                                         2                                              3
              大学附属江宁医院妇产科,江苏 南京               211100

             [摘    要] 目的:通过分析ⅠB~ⅡA1期宫颈癌术后具有中危因素患者进行单纯化疗或放疗的预后和生活质量,探讨此类患者
              术后单纯辅助化疗的可行性。方法:对2010年1月至2017年6月在南京医科大学第一附属医院妇产科接受宫颈癌根治术的术
              后病理具有中危因素的ⅠB~ⅡA1期患者113例进行回顾性分析。根据术后辅助治疗方式分为化疗组56例,放疗组57例,比
              较两组患者治疗后疗效以及生活质量的差异。结果:化疗组和放疗组在平均年龄、病理类型和临床分期上均没有统计学差
              异。化疗组患者 3 年无瘤生存率和总生存率分别为 92.8%和 96.4%,放疗组患者 3 年无瘤生存率和总生存率分别为 91.2%和
              96.5%,两组比较均无统计学差异(P>0.05)。化疗组在躯体功能、角色功能、社会功能、食欲及总体生活质量方面均优于放疗
              组。在不良反应方面,化疗组出现淋巴水肿、绝经症状的概率均低于放疗组,差异有统计学意义(P<0.05)。化疗组的性生活
              保持率(66.1%,37/56)高于放疗组(40.4%,23/57),性满意度也显著高于放疗组(P<0.05),而放疗组患者更容易出现性焦虑和
              性生活障碍(P<0.05)。结论:对ⅠB~ⅡA1期宫颈癌根治术后具有中危因素的患者,采用单纯辅助化疗也可获得较好疗效,总
              体生活质量优于放疗患者。
             [关键词] 宫颈癌;中危因素;生活质量;化疗;放疗

             [中图分类号] R737.33                   [文献标志码] A                       [文章编号] 1007⁃4368(2021)01⁃092⁃06
              doi:10.7655/NYDXBNS20210117



              Analysis of postoperative chemotherapy,radiotherapy and quarlity of life for intermediate
              risk cervical cancer patients in FIGO stage ⅠB~ⅡA1

                            1           2            2     3           2*
              YANG Yingqian ,ZHOU Delan ,HAN Nannan ,LI Su ,HAN Suping
              1 Department of Gynecology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029;
               Department of Obstetrics and Gynecology,the First Affiliated Hospital of Nanjing Medical University,Nanjing
              2
                     3
              210036;Department of Obstetrics and Gynecology,the Affiliated Jiangning Hospital of Nanjing Medical University,
              Nanjing 211100,China


             [Abstract] Objective:To investigate the efficacy of postoperative chemotherapy in patients with intermediate risk factors by
              analyzing the prognosis and life quality of patients undergoing postoperative chemotherapy or radiotherapy. Methods:A retrospective
              study was conducted on 113 patients at the First Affiliated Hospital of Nanjing Medical University who underwent hysterectomy for
              clinical stage ⅠB~ⅡA1 with intermediate risk factors during January,2010 to June,2017. Of these patients,56 patients had adjuvant
              chemotherapy,and 57 patients had radiotherapy. The disease ⁃ free survival(DFS),overall survival(OS)and quality of life were
              compared between the two groups. Results:There was no significant difference in age and pathological type between the two groups.
              Three⁃year DFS rates and OS rates were 92.8%,96.4% in chemotherapy group,and 91.2%,96.5% in radiotherapy group. There were
              no statistically significant difference(P>0.05). There were significant differences in body function,role function,social function,
              appetite and overall quality of life between chemotherapy groupand radiotherapy group,and the former was superior to the latter. In
              side effects,the chance of lymphedema and menopause symptoms were lower in chemotherapy group than in radiotherapy group,and
              the difference was statistically significant(P < 0.05). There are more persons that still have sex in chemotherapy group than in
             [基金项目] 南京医科大学“十二五”教育研究课题(JYY2015034)
              ∗
              通信作者(Corresponding author),E⁃mail:han⁃suping@hotmail.com
   93   94   95   96   97   98   99   100   101   102   103